PRS4 Economic Evaluation of the Use of Palivizumab as Prophylactic Treatment for the Reduction of Complications Associated With Respiratory Syncytial Virus in Pre-Term Patients
Value in Health - United Kingdom
doi 10.1016/j.jval.2011.08.1698
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2011
Authors
Publisher
Elsevier BV